-
Aravive Highlights Updated Batiraxcept Data From Kidney Cancer Trial
Thursday, March 3, 2022 - 11:06am | 230Read More...Aravive Inc (NASDAQ: ARAV) has announced new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC). 26 previously treated ccRCC patients have been treated with batiraxcept at doses of 15 mg/kg (n=16) and 20 mg/kg (n=10...
-
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
Thursday, February 17, 2022 - 12:23pm | 287Read More...Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (RCC). The data were presented at the American Society of Clinical Oncology (ASCO...
-
Merck's Keytruda Scores First Approval In Adjuvant Kidney Cancer Setting
Thursday, November 18, 2021 - 10:53am | 247Read More...The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, for the adjuvant treatment of renal cell carcinoma (RCC). The news comes almost half a year after Merck took the stage at ASCO to report Phase 3 data showing Keytruda cut the risk of cancer...
-
See Why Sonnet BioTherapeutics Stock Is Skyrocketing In Premarket Tuesday
Tuesday, August 31, 2021 - 5:43am | 266Read More...Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) stock is soaring during premarket in reaction to the selection of SON-1410 as a development candidate for melanoma and renal cancers. SON-1410 represents Sonnet's second bispecific compound integrating Interleukin 12 (IL-12...
-
Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer
Tuesday, July 6, 2021 - 10:39am | 241Read More...Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is the first tumor-targeted investigational medicine to utilizing Arrowhead's Targeted...
-
Merck's Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting
Friday, June 4, 2021 - 7:20am | 274Read More...Merck & Co (NYSE: MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma (RCC). The trial included RCC patients at intermediate-high or high risk of...
-
Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer
Thursday, April 8, 2021 - 8:26am | 222Read More...Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic...
-
Merck's Belzutifan Wins Priority Review Status In Type Of Kidney Cancer
Tuesday, March 16, 2021 - 12:24pm | 271Read More...The FDA has granted Priority Review designation to Merck & Co (NYSE: MRK) Belzutifan, formerly known as PT2977. The drug candidate was considered the centerpiece in Merck’s 2019 over $1billion buyout of Peloton Therapeutics. Belzutifan’s application seeks...
-
Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer
Friday, March 12, 2021 - 9:36am | 342Read More...AVEO Pharmaceuticals Inc (NASDAQ: AVEO) has entered into a collaboration and supply agreement with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate the former's Fotivda (tivozanib) in combination with the latter's Opdivo (nivolumab). The Phase 3 TiNivo-2...
-
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
Thursday, March 11, 2021 - 9:21am | 769Read More...The FDA has finally approved AVEO Pharmaceuticals Inc’s (NASDAQ: AVEO) tivozanib for advanced renal cell carcinoma, nine years after it first submitted its marketing application to the agency. The label covers relapsed or refractory renal cell carcinoma who have received...
-
European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Friday, February 26, 2021 - 1:55pm | 229Read More...European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) in combination with Bristol-Myers Squibb Co's (NYSE: BMY)...
-
Merck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study
Tuesday, February 16, 2021 - 2:19pm | 396Read More...Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OCTMKT: ESALY) unveiled new data from the Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating a combo of Merck’s Keytruda and Eisai’s Lenvima (lenvatinib) or Lenvima plus chemotherapy everolimus...
-
Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer
Tuesday, February 16, 2021 - 10:01am | 386Read More...Exelixis Inc (NASDAQ: EXEL) has reported new data from the Phase 2 (PAPMET) study evaluating CABOMETYX (cabozantinib) compared with Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in patients with metastatic papillary renal cell carcinoma (PRCC), a form of...
